Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis

References

• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046–e1081. doi: 10.1161/CIR.0000000000000699.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438–445. doi: 10.1016/j.jacc.2006.04.070.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi: 10.1093/eurheartj/ehaa575.
   PubMed Web of Science ®Google Scholar
• Vogel B, Claessen BE, Arnold SV, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primers. 2019;5(1):39. doi: 10.1038/s41572-019-0090-3.
   PubMed Web of Science ®Google Scholar
• Silverio A, Cancro FP, Esposito L, et al. Secondary cardiovascular prevention after acute coronary syndrome: emerging risk factors and novel therapeutic targets. J Clin Med. 2023;12(6):2161. doi: 10.3390/jcm12062161.
   PubMedGoogle Scholar
• Hess CN, Clare RM, Neely ML, et al. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017;187:194–203. doi: 10.1016/j.ahj.2017.01.016.
   PubMedGoogle Scholar
• Kaasenbrood L, Boekholdt SM, van der Graaf Y, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation. 2016;134(19):1419–1429. doi: 10.1161/CIRCULATIONAHA.116.021314.
   PubMed Web of Science ®Google Scholar
• Gao Y, Shah LM, Ding J, et al. US trends in cholesterol screening, lipid levels, and lipid-lowering medication use in US adults, 1999 to 2018. J Am Heart Assoc. 2023;12(3):e028205. doi: 10.1161/JAHA.122.028205.
   PubMedGoogle Scholar
• Lee S, Cannon CP. Combination lipid-lowering therapies for the prevention of recurrent cardiovascular events. Curr Cardiol Rep. 2018;20(7):55. doi: 10.1007/s11886-018-0997-4.
   PubMedGoogle Scholar
• Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155–165. doi: 10.1038/s41569-018-0107-8.
   PubMed Web of Science ®Google Scholar
• Gunta SP, O’Keefe JH, O’Keefe EL, et al. PCSK9 inhibitor, ezetimibe, and bempedoic acid: evidence-based therapies for statin-intolerant patients. Prog Cardiovasc Dis. 2023;79:12–18. doi: 10.1016/j.pcad.2023.02.007.
   PubMedGoogle Scholar
• Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol. 2020;878:173114. doi: 10.1016/j.ejphar.2020.173114.
   PubMedGoogle Scholar
• Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: a Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guide­lines. Circulation. 2023;148(9):e9–e119. doi: 10.1161/CIR.0000000000001168.
   PubMedGoogle Scholar
• Zhan S, Tang M, Liu F, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11(11):CD012502. doi: 10.1002/14651858.CD012502.pub2.
   PubMedGoogle Scholar
• Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022;377:e069116. doi: 10.1136/bmj-2021-069116.
   PubMedGoogle Scholar
• Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022; Jul 30400(10349):380–390. doi: 10.1016/S0140-6736(22)00916-3.
   PubMedGoogle Scholar
• Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023; Apr 529:100624. doi: 10.1016/j.lanepe.2023.100624.
   PubMedGoogle Scholar
• Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022;377:e069066. doi: 10.1136/bmj-2021-069066.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from https://www.training.cochrane.org/handbook.
   Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi: 10.1136/bmj.39489.470347.AD.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a Microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5(1):52. doi: 10.1186/1756-0500-5-52.
   PubMedGoogle Scholar
• Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore). 2019;98(23):e15987. doi: 10.1097/MD.0000000000015987.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646. doi: 10.1161/CIR.0000000000000725.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi: 10.1056/NEJMoa1410489.
   PubMed Web of Science ®Google Scholar
• Hao Y, Yang YL, Wang YC, et al. Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome. Int Heart J. 2022;63(4):669–677. doi: 10.1536/ihj.22-052.
   PubMedGoogle Scholar
• Japaridze L, Sadunishvili M. The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender. Kardiol Pol. 2017;75(8):770–778. doi: 10.5603/KP.a2017.0074.
   PubMedGoogle Scholar
• Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of ldl cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452–2462. doi: 10.1016/j.jacc.2019.08.010.
   PubMed Web of Science ®Google Scholar
• Liu Z, Hao H, Yin C, et al. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget. 2017;8(25):41582–41589. doi: 10.18632/oncotarget.15078.
   PubMedGoogle Scholar
• Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. Jama. 2022;327(18):1771–1781. doi: 10.1001/jama.2022.5218.
   PubMed Web of Science ®Google Scholar
• Ran D, Nie HJ, Gao YL, et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol. 2017;235:49–55. doi: 10.1016/j.ijcard.2017.02.099.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi: 10.1056/NEJMoa1801174.
   PubMed Web of Science ®Google Scholar
• Tan H, Liu L, Zheng Q, et al. Effects of combined lipid-lowering therapy on low-density lipoprotein cholesterol variability and cardiovascular adverse events in patients with acute coronary syndrome. Adv Ther. 2021;38(6):3389–3398. doi: 10.1007/s12325-021-01741-7.
   PubMedGoogle Scholar
• Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; Oct 1244(38):3720–3826. doi: 10.1093/eurheartj/ehad191.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022; Oct 11146(15):1109–1119. doi: 10.1161/CIRCULATIONAHA.122.061620.
   PubMed Web of Science ®Google Scholar
• Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172–1180. doi: 10.1093/eurheartj/ehx566.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319(15):1566–1579. doi: 10.1001/jama.2018.2525.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Kim JS, Labreuche J, et al. Yield of dual therapy with statin and ezetimibe in the treat stroke to target trial. Stroke. 2022;53(11):3260–3267. doi: 10.1161/STROKEAHA.122.039728.
   PubMedGoogle Scholar
• Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015; Aug 466(5):495–507. doi: 10.1016/j.jacc.2015.05.065.
   PubMed Web of Science ®Google Scholar
• Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017; Aug 138(29):2264–2276. PMID: 28430910; PMCID: PMC5837267. doi: 10.1093/eurheartj/ehx162.
   PubMedGoogle Scholar
• Watts GF, Chan DC, Pang J, et al. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). Metabolism. 2020;107:154221. doi: 10.1016/j.metabol.2020.154221.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483–1492. doi: 10.1161/CIRCULATIONAHA.118.037184.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Giugliano RP. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Curr Opin Lipidol. 2022;33(3):147–159. doi: 10.1097/MOL.0000000000000830.
   PubMedGoogle Scholar
• Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018;39(27):2540–2545. doi: 10.1093/eurheartj/ehx450.
   PubMed Web of Science ®Google Scholar
• Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–261. doi: 10.1016/j.atherosclerosis.2012.02.016.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499. doi: 10.1056/NEJMoa1501031.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87. doi: 10.4158/EP171764.APPGL.
   PubMed Web of Science ®Google Scholar
• Editorial Board of Chinese Journal of Cardiology. [Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(4):280–286. doi: 10.3760/cma.j.cn112148-20200121-00036.
   PubMedGoogle Scholar